I think it's hopeful

[Eunseoc]

prnewswire.com/news-release...

article about trehalose.

I think the basic concept of the medication is fundamental.

I wish the medi comes soon aqas.

Do you have any information about this?

[wobblybee]

🙂 copied from the link

Seelos' Phase II/III trial (NCT05490563) plans to enroll up to 245 participants globally with spinocerebellar ataxia type-3 in a double-blind, randomized, placebo-controlled trial. 

‘Globally’ is optimistic news

🙂There is also this..

Funding for SCA3 research project

Ataxia UK is very pleased to award funding to Dr Andreia Teixeira-Castro at the University of Minho in Portugal, for her research project testing an antidepressant as a potential treatment for SCA3.

Spinocerebellar ataxia type 3 (SCA3) is an inherited ataxia caused by a change to the ATXN3 gene. The ATXN3 gene is responsible for producing a protein called ataxin-3. The change to the ATXN3 gene causes the ataxin-3 protein to become sticky and clump together.

These protein clumps are toxic to brain cells, and result in the symptoms of SCA3. Dr Teixeira-Castro and her team will study whether treatment with an antidepressant could improve the motor symptoms of SCA3 in animal models.

Serotonin is a chemical produced in the brain, which has several important functions, including roles in emotion and motor skills. The presence of serotonin in the brain reduces depression. For this reason, drugs which increase the amount of serotonin in the brain are routinely used as antidepressants.

These researchers previously showed that prolonged treatment with an antidepressant called citalopram, which increases serotonin levels, improved motor symptoms of SCA3in animal models.

They also found that treatment with citalopram reduced the amount of toxic ataxin-3 protein in these animal models.

This work showed that targeting the serotonin systems in the brain could be a successful treatment option for SCA3.

Given these promising results, they will now investigate the effect of further increasing serotonin action in the brain by using a different antidepressant, called vortioxetine. Vortioxetine simultaneously targets a number of pathways within the brain, which work together to increase the amount and activity of serotonin.

These researchers think that by further increasing the amount and activity of serotonin in the brain, they could achieve an even greater reduction in motor symptoms in SCA3 animal models. They plan to test the treatment both in mice that have yet to develop symptoms, to see if symptom onset could be delayed, and in mice with established symptoms, to see if progression of SCA3 symptoms can be slowed.

Dr Teixeira-Castro and her team will compare the effect of citalopram and vortioxetine treatment on SCA3 mice. The results of this comparison will be used to plan clinical trials, and could also be tested in other ataxias in the future.

Copied from ataxia.org.uk

[Eunseoc in reply to wobblybee]

Thanks7

[7151 in reply to Eunseoc]

Intéressant but i m not kean on antidépresseurs 🙁

[Eunseoc in reply to 7151]

what does it mean?